Trevena to Host Conference Call on March 18th to Discuss Full Year 2014 Financial Results
- Wall St set for lower open ahead of service-sector data
- Morgan Stanley's Wilson is a stock seller again as tactical rally plays out
- Activision Blizzard rallies on report Microsoft 'ready to fight' FTC to complete deal
- Tesla (TSLA) cuts December Model Y output at Shanghai plant
- Oil up 3% on OPEC+ output plans and price cap on Russian crude
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company, today announced that it will host a conference call on Wednesday, March 18, 2015 at 8:30 a.m. Eastern Time to discuss corporate updates and financial results for the year ended December 31, 2014.
The call can be accessed by dialing (855) 465-0180 (U.S. and Canada) or (484) 756-4313 (international), and entering passcode 98326456.
To access a live audio webcast of the presentation, please visit the “Investors” section at trevenainc.com. Following the conclusion of the presentation, the webcast will be archived and available for replay on the company's website for 30 days. A replay of the call will be available for 30 days and can be accessed by dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international), and entering passcode 98326456.
Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena is developing four biased ligand product candidates it has identified - TRV027 to treat acute heart failure (Phase 2b), TRV130 to treat moderate to severe acute pain intravenously (Phase 2b), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for treatment-refractory migraine and other CNS disorders (Preclinical).
Jonathan Violin, 610-354-8840 x231
Director, Investor Relations
Andrea Rabney, 212-600-1902
President and Chief Executive Officer
Argot Partners, 917-763-8106
Source: Trevena, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- V.F. Corp. (VFC) North Face parent VF Corp trades lower after CEO exit, guidance cut
- Meihua International Medical Technologies Co., Ltd. Appoints New CEO, CFO and Directors
- SOLO UNVEILS FIRST-EVER RE:CYCLED LUGGAGE LINE
Create E-mail Alert Related CategoriesPress Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!